Plasma thrombospondin 1 as a predictor of postoperative liver dysfunction

British Journal of Surgery

Volumn 102, Issue 7, 2015, Pages 826-836

  Starlinger, P ^a   Haegele, S ^a   Wanek, D ^a   Zikeli, S ^a   Schauer, D ^a   Alidzanovic, L ^a   Fleischmann, E ^b   Gruenberger, B ^c   Gruenberger, T ^a   Brostjan, C ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c NONE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOSPONDIN 1;

ADULT; ADVERSE EFFECTS; AGED; BLOOD; FEMALE; FOLLOW UP; HUMAN; LIVER DISEASES; LIVER NEOPLASMS; LIVER RESECTION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; LIVER DISEASES; LIVER NEOPLASMS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; ROC CURVE; THROMBOSPONDIN 1; YOUNG ADULT;

EID: 84929026291     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9814     Document Type: Article

References (27)

1. Wei AC, Tung-Ping Poon R, Fan ST, Wong J,. Risk factors for perioperative morbidity and mortality after extended hepatectomy for hepatocellular carcinoma. Br J Surg 2003; 90: 33-41.
2. Mullen JT, Ribero D, Reddy SK, Donadon M, Zorzi D, Gautam S, et al. Hepatic insufficiency and mortality in 1059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg 2007; 204: 854-862.
3. Michalopoulos GK,. Liver regeneration. J Cell Physiol 2007; 213: 286-300.
4. Clavien PA,. Liver regeneration: a spotlight on the novel role of platelets and serotonin. Swiss Med Wkly 2008; 138: 361-370.
5. McMahon JB, Richards WL, del Campo AA, Song MK, Thorgeirsson SS,. Differential effects of transforming growth factor-beta on proliferation of normal and malignant rat liver epithelial cells in culture. Cancer Res 1986; 46: 4665-4671.
6. Bonnefoy A, Moura R, Hoylaerts MF,. The evolving role of thrombospondin-1 in hemostasis and vascular biology. Cell Mol Life Sci 2008; 65: 713-727.
7. Lawler PR, Lawler J,. Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb Perspect Med 2012; 2: a006627.
8. Starlinger P, Moll HP, Assinger A, Nemeth C, Hoetzenecker K, Gruenberger B, et al. Thrombospondin-1: a unique marker to identify in vitro platelet activation when monitoring in vivo processes. J Thromb Haemost 2010; 8: 1809-1819.
9. Adams JC, Bentley AA, Kvansakul M, Hatherley D, Hohenester E,. Extracellular matrix retention of thrombospondin 1 is controlled by its conserved C-terminal region. J Cell Sci 2008; 121: 784-795.
10. Sweetwyne MT, Pallero MA, Lu A, Van Duyn Graham L, Murphy-Ullrich JE,. The calreticulin-binding sequence of thrombospondin 1 regulates collagen expression and organization during tissue remodeling. Am J Pathol 2010; 177: 1710-1724.
11. Sid B, Sartelet H, Bellon G, El Btaouri H, Rath G, Delorme N, et al. Thrombospondin 1: a multifunctional protein implicated in the regulation of tumor growth. Crit Rev Oncol Hematol 2004; 49: 245-258.
12. Hayashi H, Sakai K, Baba H, Sakai T,. Thrombospondin-1 is a novel negative regulator of liver regeneration after partial hepatectomy through transforming growth factor-beta1 activation in mice. Hepatology 2012; 55: 1562-1573.
13. Starlinger P, Schauer D, Alidzanovic L, Zikeli S, Gebhardt K, Luf F, et al. Clinical evidence for thrombospondin-1 as a relevant suppressor of liver regeneration. J Hepatol 2013; 58: 1053-1054.
14. Strasberg SM,. Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg 2005; 12: 351-355.
15. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM,. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005; 93: 387-391.
16. Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R, et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery 2011; 149: 713-724.
17. Dindo D, Demartines N, Clavien PA,. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205-213.
18. Starlinger P, Alidzanovic L, Schauer D, Brugger P, Sommerfeldt S, Kuehrer I, et al. Platelet-stored angiogenesis factors: clinical monitoring is prone to artifacts. Dis Markers 2011; 31: 55-65.
19. Starlinger P, Brugger P, Schauer D, Sommerfeldt S, Tamandl D, Kuehrer I, et al. Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between chemotherapy and anti-VEGF treatment. Neoplasia 2011; 13: 419-427.
20. Brostjan C, Gebhardt K, Gruenberger B, Steinrueck V, Zommer H, Freudenthaler H, et al. Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels. Clin Cancer Res 2008; 14: 2065-2074.
21. Krieger PM, Tamandl D, Herberger B, Faybik P, Fleischmann E, Maresch J, et al. Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing. Ann Surg Oncol 2011; 18: 1644-1650.
22. Yamanaka N, Okamoto E, Kawamura E, Kato T, Oriyama T, Fujimoto J, et al. Dynamics of normal and injured human liver regeneration after hepatectomy as assessed on the basis of computed tomography and liver function. Hepatology 1993; 18: 79-85.
23. Switalska HI, Niewiarowski S, Tuszynski GP, Rucinski B, Schmaier AH, Morinelli TA, et al. Radioimmunoassay of human platelet thrombospondin: different patterns of thrombospondin and beta-thromboglobulin antigen secretion and clearance from the circulation. J Lab Clin Med 1985; 106: 690-700.
24. Aiken ML, Ginsberg MH, Plow EF,. Divalent cation-dependent and independent surface expression of thrombospondin on thrombin-stimulated human platelets. Blood 1987; 69: 58-64.
25. Murphy-Ullrich JE, Mosher DF,. Interactions of thrombospondin with endothelial cells: receptor-mediated binding and degradation. J Cell Biol 1987; 105: 1603-1611.
26. Mikhailenko I, Krylov D, Argraves KM, Roberts DD, Liau G, Strickland DK,. Cellular internalization and degradation of thrombospondin-1 is mediated by the amino-terminal heparin binding domain (HBD). High affinity interaction of dimeric HBD with the low density lipoprotein receptor-related protein. J Biol Chem 1997; 272: 6784-6791.
27. Lee NV, Sato M, Annis DS, Loo JA, Wu L, Mosher DF, et al. ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2. EMBO J 2006; 25: 5270-5283.